Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001683168-25-007760
Filing Date
2025-10-24
Accepted
2025-10-24 16:00:46
Documents
15
Period of Report
2025-11-17

Document Format Files

Seq Description Document Type Size
1 DEF 14A cns_def14a.htm   iXBRL DEF 14A 492072
  Complete submission text file 0001683168-25-007760.txt   894637

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE cnsp-20251117.xsd EX-101.SCH 3419
3 XBRL DEFINITION FILE cnsp-20251117_def.xml EX-101.DEF 5345
4 XBRL LABEL FILE cnsp-20251117_lab.xml EX-101.LAB 84663
5 XBRL PRESENTATION FILE cnsp-20251117_pre.xml EX-101.PRE 63237
17 EXTRACTED XBRL INSTANCE DOCUMENT cns_def14a_htm.xml XML 2366
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

EIN.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39126 | Film No.: 251416107
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)